细胞免疫治疗联合铂类化疗可延长非小细胞肺癌患者的生存期。

IF 2 4区 医学 Q3 ONCOLOGY Neoplasma Pub Date : 2023-04-01 DOI:10.4149/neo_2023_230127N44
Lei Qian, Xiao Ding, Fang-Qi Li, Hui-Min Tian, Xiao Chen, Fu-Jun Han, Hong-Yi Wang, Wen-Qian Li, Chao Niu, Jian-Ting Xu, Zhao-Zhi Li, Hua He, Jiu-Wei Cui
{"title":"细胞免疫治疗联合铂类化疗可延长非小细胞肺癌患者的生存期。","authors":"Lei Qian,&nbsp;Xiao Ding,&nbsp;Fang-Qi Li,&nbsp;Hui-Min Tian,&nbsp;Xiao Chen,&nbsp;Fu-Jun Han,&nbsp;Hong-Yi Wang,&nbsp;Wen-Qian Li,&nbsp;Chao Niu,&nbsp;Jian-Ting Xu,&nbsp;Zhao-Zhi Li,&nbsp;Hua He,&nbsp;Jiu-Wei Cui","doi":"10.4149/neo_2023_230127N44","DOIUrl":null,"url":null,"abstract":"<p><p>Platinum-based chemotherapy is the primary treatment option for advanced non-small cell lung cancer (NSCLC) patients without a driver gene mutation, but its efficacy is still modest. Through a potential synergistic effect, autologous cellular immunotherapy (CIT) composed of cytokine-induced killer (CIK), natural killer (NK), and T cells might enhance it. NK cells exhibited in vitro cytotoxicity toward lung cancer cells (A549 cells) following platinum therapy. Using flow cytometry, the expression of MICA, MICB, DR4, DR5, CD112, and CD155 on lung cancer cells was assessed. In this retrospective cohort study, there were included 102 previously untreated stage IIIB/IV NSCLC patients ineligible for tyrosine kinase inhibitor (TKI) target therapy who received either chemotherapy alone (n=75) or combination therapy (n=27). The cytotoxicity of NK cells for A549 cells was increased obviously and a time-dependent enhancement of this effect was also observed. After platinum therapy, the levels of MICA, MICB, DR4, DR5, CD112, and CD155 on the surface of A549 cells were increased. In the combination group, the median PFS was 8.3 months, compared to 5.5 months in the control group (p=0.042); the median overall survival was 18.00 months, compared to 13.67 months in the combined group (p=0.003). The combination group had no obvious immune-related adverse effects. The combination of NK cells with platinum showed synergistic anticancer effects. Combining the two strategies increased survival with minor adverse effects. Incorporating CIT into conventional chemotherapy regimens may improve NSCLC treatment. However, additional evidence will require multicenter randomized controlled trials.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 2","pages":"251-259"},"PeriodicalIF":2.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cellular immunotherapy combined with platinum-based chemotherapy prolongs survival for non-small cell lung cancer patients.\",\"authors\":\"Lei Qian,&nbsp;Xiao Ding,&nbsp;Fang-Qi Li,&nbsp;Hui-Min Tian,&nbsp;Xiao Chen,&nbsp;Fu-Jun Han,&nbsp;Hong-Yi Wang,&nbsp;Wen-Qian Li,&nbsp;Chao Niu,&nbsp;Jian-Ting Xu,&nbsp;Zhao-Zhi Li,&nbsp;Hua He,&nbsp;Jiu-Wei Cui\",\"doi\":\"10.4149/neo_2023_230127N44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Platinum-based chemotherapy is the primary treatment option for advanced non-small cell lung cancer (NSCLC) patients without a driver gene mutation, but its efficacy is still modest. Through a potential synergistic effect, autologous cellular immunotherapy (CIT) composed of cytokine-induced killer (CIK), natural killer (NK), and T cells might enhance it. NK cells exhibited in vitro cytotoxicity toward lung cancer cells (A549 cells) following platinum therapy. Using flow cytometry, the expression of MICA, MICB, DR4, DR5, CD112, and CD155 on lung cancer cells was assessed. In this retrospective cohort study, there were included 102 previously untreated stage IIIB/IV NSCLC patients ineligible for tyrosine kinase inhibitor (TKI) target therapy who received either chemotherapy alone (n=75) or combination therapy (n=27). The cytotoxicity of NK cells for A549 cells was increased obviously and a time-dependent enhancement of this effect was also observed. After platinum therapy, the levels of MICA, MICB, DR4, DR5, CD112, and CD155 on the surface of A549 cells were increased. In the combination group, the median PFS was 8.3 months, compared to 5.5 months in the control group (p=0.042); the median overall survival was 18.00 months, compared to 13.67 months in the combined group (p=0.003). The combination group had no obvious immune-related adverse effects. The combination of NK cells with platinum showed synergistic anticancer effects. Combining the two strategies increased survival with minor adverse effects. Incorporating CIT into conventional chemotherapy regimens may improve NSCLC treatment. However, additional evidence will require multicenter randomized controlled trials.</p>\",\"PeriodicalId\":19266,\"journal\":{\"name\":\"Neoplasma\",\"volume\":\"70 2\",\"pages\":\"251-259\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neoplasma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4149/neo_2023_230127N44\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neoplasma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4149/neo_2023_230127N44","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

铂类化疗是无驱动基因突变的晚期非小细胞肺癌(NSCLC)患者的主要治疗选择,但其疗效仍然有限。细胞因子诱导的杀伤细胞(CIK)、自然杀伤细胞(NK)和T细胞组成的自体细胞免疫疗法(CIT)可能通过潜在的协同作用增强其免疫功能。NK细胞在铂治疗后对肺癌细胞(A549细胞)表现出体外细胞毒性。采用流式细胞术检测肺癌细胞中MICA、MICB、DR4、DR5、CD112、CD155的表达。在这项回顾性队列研究中,纳入了102例先前未接受治疗的iii期ib /IV期NSCLC患者,这些患者不适合酪氨酸激酶抑制剂(TKI)靶向治疗,他们接受了单独化疗(n=75)或联合化疗(n=27)。NK细胞对A549细胞的细胞毒性明显增强,且随时间的增加而增强。铂治疗后,A549细胞表面MICA、MICB、DR4、DR5、CD112、CD155水平升高。联合治疗组的中位PFS为8.3个月,对照组为5.5个月(p=0.042);中位总生存期为18.00个月,而联合治疗组为13.67个月(p=0.003)。联合用药组未见明显免疫相关不良反应。NK细胞与铂的结合具有协同抗癌作用。结合这两种策略增加了生存率,副作用较小。将CIT纳入常规化疗方案可能改善非小细胞肺癌的治疗。然而,更多的证据需要多中心随机对照试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cellular immunotherapy combined with platinum-based chemotherapy prolongs survival for non-small cell lung cancer patients.

Platinum-based chemotherapy is the primary treatment option for advanced non-small cell lung cancer (NSCLC) patients without a driver gene mutation, but its efficacy is still modest. Through a potential synergistic effect, autologous cellular immunotherapy (CIT) composed of cytokine-induced killer (CIK), natural killer (NK), and T cells might enhance it. NK cells exhibited in vitro cytotoxicity toward lung cancer cells (A549 cells) following platinum therapy. Using flow cytometry, the expression of MICA, MICB, DR4, DR5, CD112, and CD155 on lung cancer cells was assessed. In this retrospective cohort study, there were included 102 previously untreated stage IIIB/IV NSCLC patients ineligible for tyrosine kinase inhibitor (TKI) target therapy who received either chemotherapy alone (n=75) or combination therapy (n=27). The cytotoxicity of NK cells for A549 cells was increased obviously and a time-dependent enhancement of this effect was also observed. After platinum therapy, the levels of MICA, MICB, DR4, DR5, CD112, and CD155 on the surface of A549 cells were increased. In the combination group, the median PFS was 8.3 months, compared to 5.5 months in the control group (p=0.042); the median overall survival was 18.00 months, compared to 13.67 months in the combined group (p=0.003). The combination group had no obvious immune-related adverse effects. The combination of NK cells with platinum showed synergistic anticancer effects. Combining the two strategies increased survival with minor adverse effects. Incorporating CIT into conventional chemotherapy regimens may improve NSCLC treatment. However, additional evidence will require multicenter randomized controlled trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neoplasma
Neoplasma 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
238
审稿时长
3 months
期刊介绍: The journal Neoplasma publishes articles on experimental and clinical oncology and cancer epidemiology.
期刊最新文献
Six2 regulates the malignant progression and 5-FU resistance of hepatocellular carcinoma through the PI3K/AKT/mTOR pathway and DNMT1/E-cadherin methylation mechanism. Protein level of epithelial membrane protein (EMP) 1, EMP 2, and EMP 3 in carcinoma of unknown primary. The impact of c-Met inhibition on molecular features and metastatic potential of melanoma cells. The real-world comparison of non-small cell lung cancer survival outcomes depending on immunotherapy treatment and PD-L1 expression level. Albumin bound-paclitaxel combined with anlotinib and immunotherapy in the second-line treatment of ES-SCLC: a retrospective cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1